News | February 20, 2013

FDA Committee Recommends Approval of Guerbet’s Macrocyclic, Ionic Gadolinium MRI Contrast Agent

Dotarem Guebert LLC FDA NDA Approval Contrast Media MRI Systems

February 20, 2013 — Guerbet announced that the Medical Imaging Drugs Advisory Committee to U.S. Food and Drug Administration (FDA) has voted unanimously by votes of 17 to zero to recommend that FDA approve the New Drug Application (NDA) for Dotarem (gadoterate meglumine) for adults, and for pediatric use for children two years of age and older. The committee voted 10 to six (with one member abstaining) not to recommend at this time approval of the indication for children under two years of age.

Dotarem is the only macrocyclic and ionic gadolinium-based contrast agent (GBCA) for the intravenous use with magnetic resonance imaging (MRI) in the brain (intracranial), spine and associated tissues in adults and pediatric patients to detect and visualize areas with disruption of the blood-brain barrier (BBB) and/or abnormal vascularity. The Guerbet NDA recommended dose is 0.1 mmol Gd/kg.

"Guerbet is very pleased with the Advisory Committee's recommendation to approve Dotarem based on our comprehensive presentation of clinical and post-marketing data," said Yves L'Epine, CEO of Guerbet Group. "If approved by FDA, we believe Dotarem can provide another CNS imaging option for U.S. clinicians. We are disappointed that the recommendation does not include the indication for children under two years of age, but we take the committee's comments very seriously and will work to address all FDA questions and concerns."

The Dotarem data presented at today's advisory committee meeting included results from two well-controlled Phase III clinical studies. These studies evaluated the diagnostic efficacy of Dotarem in magnetic resonance imaging of diseases of the central nervous system, such as primary or secondary tumors of the brain or spinal cord, inflammatory diseases such as multiple sclerosis and vascular brain diseases.

Both studies evaluated the superiority of the enhanced images over the unenhanced images for central nervous system (CNS) lesion visualization in all three co-primary endpoints. All defined primary and key secondary efficacy analyses were met and support the efficacy of Dotarem® at a standard dose of 0.1 mmol/kg BW. In addition to these two studies, 21 supportive clinical studies evaluated the efficacy of Dotarem-enhanced MRI.

Efficacy of Dotarem in the CNS indication for the pediatric population from zero to 17 years of age was assessed in pivotal study DGD-44-050 and in three open-label, single-group, non-randomized studies (DGD-3-15, DGD-3-16 and DGD-3-29).

MRI has become the mainstay of central nervous system imaging since its introduction over 20 years ago. It is estimated that there were more than 10 million contrast enhanced MRI examinations performed in the United States in 2011, with approximately 60 percent of these examinations performed to image the CNS.

The New Drug Application for gadoterate meglumine was submitted to the FDA on Sept. 20, 2012 and received priority review due to no other GBCA's being approved for children zero to two years of age. The Advisory Committee's recommendations are not binding, but FDA reviewers will consider the panel's recommendation in the final assessment of the NDA.

For more information:

Related Content

Siemens Healthineers Launches New Partners for Digital Ecosystem at HIMSS 2018
News | PACS Accessories | March 12, 2018
At the 2018 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition, March 5-9...
Alternative Technique Can Improve Brain Imaging for Restless Children
News | Pediatric Imaging | March 08, 2018
March 8, 2018 – Children often find it difficult to remain still for...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
Imaging Plays Key Role in Evaluating Injuries at Olympics
News | Orthopedic Imaging | February 28, 2018
The Olympic Games give elite athletes a chance at athletic triumph, but also carry a risk of injury. When injuries...
FDA Clears Siemens Healthineers' GOKnee3D MRI Application
Technology | Magnetic Resonance Imaging (MRI) | February 19, 2018
The U.S. Food and Drug Administration (FDA) has cleared GOKnee3D, a magnetic resonance imaging (MRI) application from...
Overlay Init